Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $56.32M
• Dividend Yield: N/A
• Average Volume (3M): 8.65K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.02
• Revenue Growth: 34.04%
• EPS Growth: 55.34%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -5.94
• Shares Outstanding: 9,932,215
• 10 Day Avg. Volume: 11,848
• 30 Day Avg. Volume: 8,651
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 338.74
• Price to Cash Flow (P/CF): -3.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.00
• Price Target Upside: 94.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Serina Therapeutics' stock score is primarily hindered by its severe financial challenges, including declining revenue, high liabilities, and negative cash flow. While there is some short-term technical momentum, the overall valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.

Positive Factors

Market Potential

POZ-Apomorphine targets substantial Advanced Parkinson's Disease market with potential for key clinical/commercial advantages.

Technology and Innovation

Serina's core technology is based on the polymer poly(2-oxazoline) (POZ), which facilitates improved delivery of drugs administered subcutaneously.

Negative Factors

Financial Needs

Serina will require additional capital to support development, with current cash expected to last through 2Q25.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics (SER) is a biotechnology company specializing in the development of polymer-based drug delivery platforms. The company focuses on enhancing the efficacy and safety of existing pharmaceuticals by utilizing its proprietary Polyoxazoline (POZ) technology to improve drug solubility, stability, and delivery. Serina Therapeutics operates primarily within the pharmaceutical and biotechnology sectors, offering innovative solutions to streamline drug formulation and administration.

How the Company Makes Money

Serina Therapeutics makes money through licensing agreements and partnerships with pharmaceutical companies interested in utilizing its proprietary POZ technology to enhance their drug products. These collaborations often involve upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, Serina may engage in research and development contracts, where they apply their technology to develop customized drug delivery solutions for clients, generating revenue through service fees. Partnerships with larger pharmaceutical companies also provide strategic funding, supporting the company's ongoing research and development efforts.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
56.00K	142.00K	500.00K	3.04M	54.00K	1.73M
	Gross Profit
-26.00K	-29.00K	355.00K	2.89M	-1.23M	729.50K
	EBIT
-17.05M	-9.96M	-2.27M	-1.63M	-10.41M	-12.56M
	EBITDA
-5.06M	-9.78M	-2.60M	-1.59M	-8.74M	-11.61M
	Net Income Common Stockholders
-5.56M	-14.80M	-2.68M	-1.26M	-10.87M	-12.15M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.52M	345.00K	532.23K	1.31M	527.00K	2.35M
	Total Assets
10.63M	11.96M	858.04K	1.84M	3.92M	7.44M
	Total Debt
0.00	4.37M	1.81M	398.17K	6.30M	1.96M
	Net Debt
-8.52M	4.02M	1.28M	83.33K	5.77M	-396.00K
	Total Liabilities
1.66M	6.61M	38.64M	36.95M	9.32M	4.83M
	Stockholders Equity
8.01M	5.47M	-37.78M	-35.11M	-5.12M	2.22M
Cash Flow		Free Cash Flow
-17.16M	-7.80M	-2.09M	-2.36M	-7.84M	-10.80M
	Operating Cash Flow
-17.14M	-7.80M	-2.08M	-2.25M	-7.82M	-10.16M
	Investing Cash Flow
-22.00K	-10.00M	980.94K	823.32K	-20.00K	-361.00K
	Financing Cash Flow
13.21M	17.50M	1.31M	1.08M	5.96M	6.26M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Positive. The current price of 5.67 is above the 20-day moving average (MA) of 4.68, above the 50-day MA of 4.71, and below the 200-day MA of 6.43, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 69.53 is Neutral, neither overbought nor oversold. The STOCH value of 82.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRPT	68 Neutral	$6.83B	26.78	19.71%	―	52.97%	―
VRTX	64 Neutral	$126.52B	―	-3.15%	―	11.64%	-114.72%
ALNY	59 Neutral	$34.92B	―	-414.62%	―	22.97%	38.54%
RGEN	58 Neutral	$7.49B	―	-1.30%	―	0.33%	-171.08%
IONS	49 Neutral	$4.95B	―	-93.03%	―	-10.48%	-18.79%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
SER	45 Neutral	$56.32M	―	45.59%	―	34.04%	55.34%

Serina Therapeutics Corporate Events

Serina Therapeutics Unveils Breakthrough in POZ-Lipid Technology

On March 24, 2025, Serina Therapeutics announced that its Chief Development Officer, Randall Moreadith, presented new data at the American Chemistry Society Spring 2025 Meeting. The presentation highlighted the non-immunogenic profile of Serina’s POZ-lipid technology, which did not trigger an antibody response in rats, unlike the commonly used PEG-lipid standards. This discovery could lead to safer and more effective lipid nanoparticle formulations for gene therapy and RNA-based medicines, potentially impacting the development of treatments that avoid adverse immune reactions.

Serina Therapeutics Appoints Dr. Venkatesan to Board

On February 11, 2025, Serina Therapeutics announced the appointment of Dr. Jay Venkatesan to its Board of Directors, effective February 12, 2025. Dr. Venkatesan, who has extensive experience in biotechnology investments and strategic growth, will also serve as the Audit Committee Chair. His appointment is expected to bolster Serina’s strategic vision as the company leverages its POZ Platform to develop innovative therapeutics. Concurrently, co-founder Dr. Milton Harris will transition to Director Emeritus and Chair of the Scientific Advisory Board, continuing to guide the company’s research efforts.

Serina Therapeutics Secures $5 Million for SER-252 Trials

On February 3, 2025, Serina Therapeutics announced the completion of a second $5 million tranche of a $10 million financing deal with JuvVentures, supporting the progression of SER-252 into Phase 1 clinical trials for advanced Parkinson’s disease in late 2025. This capital injection, achieved by issuing shares at a 113% premium, underlines Serina’s commitment to its innovative drug delivery platform and enhances its market positioning by potentially offering significant benefits in Parkinson’s treatment.

Serina Therapeutics Strengthens Board with New Appointment

On January 14, 2025, Serina Therapeutics announced the appointment of Karen J. Wilson to its Board of Directors, marking a significant addition due to her extensive experience in the life sciences sector. Wilson’s financial and industry expertise is expected to support Serina’s strategic initiatives and enhance its positioning in the biotechnology market. Concurrently, Steven Mintz departed from the board, with Remy Gross taking over as the chair of the Audit Committee.

Serina Therapeutics Announces SER-252 for Parkinson’s Trials

Serina Therapeutics has announced the development of its lead program, SER-252, which is set to enter clinical trials in 2025 as a novel treatment for advanced Parkinson’s disease. The POZ Platform® developed by Serina aims to optimize drug delivery and reduce immunogenicity, positioning the company as a competitive player in the biotechnology industry. The platform offers significant improvements in drug delivery, including continuous release and safe metabolism, which could greatly impact treatment options for Parkinson’s patients and potentially capture a significant market share.